Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the p...
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
About this item
Full title
Author / Creator
Glutsch, Valerie , Schummer, Patrick , Kneitz, Hermann , Gesierich, Anja , Goebeler, Matthias , Klein, Detlef , Posch, Christian , Gebhardt, Christoffer , Haferkamp, Sebastian , Zimmer, Lisa , Becker, Jürgen C , Leiter, Ulrike , Weichenthal, Michael , Schadendorf, Dirk , Ugurel, Selma and Schilling, Bastian
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62%. However, primary and second...
Alternative Titles
Full title
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1cc2750e45564ddcada930fb89b042c9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1cc2750e45564ddcada930fb89b042c9
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2022-005930
